The role of hypoxia inducible factor-1alpha in gynecological cancer

• Published in: Critical reviews in oncology/hematology 2011-06, Vol.78 (3), p.173-184
• Main Authors: Seeber, Laura M.S, Horrée, Nicole, Vooijs, Marc A.G.G, Heintz, A. Peter M, van der Wall, Elsken, Verheijen, René H.M, van Diest, Paul J
• Format: Article
• Language: English
• Subjects: Cervical cancer; Endometrial cancer; Female; Genital Neoplasms, Female - diagnosis; Genital Neoplasms, Female - metabolism; Genital Neoplasms, Female - therapy; Hematology, Oncology and Palliative Medicine; Humans; Hypoxia; Hypoxia - genetics; Hypoxia - metabolism; Hypoxia inducible factor-1alpha; Hypoxia-Inducible Factor 1, alpha Subunit - genetics; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Ovarian cancer; Prognosis; Therapy
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2010.05.003

Abstract Understanding the mechanisms of carcinogenesis and progression of gynecological tumors is important as these insights might lead to improved diagnostic tools for the pathologist, improved prediction of prognosis, response to therapy, and eventually better biology-based disease management, thereby improving prognosis and quality of life for the individual patient. Hypoxia is an important event in carcinogenesis because it renders a more aggressive phenotype with increased invasiveness and proliferation, formation of metastases and poorer survival. Although selecting patients with hypoxic tumors may therefore be clinically important, there is no consensus as to the method best suited for routine assessment of hypoxia. One of the potential tumor hypoxia markers is hypoxia inducible factor 1 (HIF-1). HIF-1 is the key cellular survival protein under hypoxia, and is associated with tumor progression and metastasis in various solid tumors. In this review, we show that in gynecological cancers, HIF-1A is emerging as an important factor in carcinogenesis, and that overexpression of HIF-1A and its target genes CA9 and SLC2A1 seems associated with shorter progression free- and overall survival. Since hypoxia and HIF-1A expression are associated with treatment failure, targeting HIF-1A could be an attractive therapeutic strategy with the potential for disrupting multiple pathways crucial for tumor growth. Currently, HIF-1A inhibitors are being studied in clinical trials in recurrent ovarian- and cervical cancer, and trials in other gynecological cancers are expected.